MedTrace Logo

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

NCT04252859 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-05-18

Study results available
· View outcomes & findings →

Summary

FES PET/CT imaging for invasive lobular cancer

Conditions

  • Invasive Lobular Breast Carcinoma

Interventions

DRUG

[18F]Fluoroestradiol (FES) PET/CT

\[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)

Sponsors & Collaborators

Principal Investigators

  • Jeffrey Yap, PhD · Huntsman Cancer Institute/ University of Utah

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-11
Primary Completion
2024-12-07
Completion
2024-12-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04252859 on ClinicalTrials.gov